Osajin displays potential antiprostate cancer efficacy via impairment of fatty acid synthase and androgen receptor expression.

These data provide a novel molecular basis of osajin in PCa cells, and cotargeting lipogenesis and the AR axis via impairment of FASN and AR expression by osajin could be applied as a new and promising approach for the treatment of malignant PCa.